American Medical Association statement on antibody treatments

Community NewsNews
298

Translate to Spanish or other 102 languages!

We are pleased that the FDA is following the scientific evidence and limiting the use of monoclonal antibody treatments to those that are effective against the Omicron variant. Image for illustration purposes.
We are pleased that the FDA is following the scientific evidence and limiting the use of monoclonal antibody treatments to those that are effective against the Omicron variant. Image for illustration purposes.

Mega Doctor News

- Advertisement -

Gerald E. Harmon, M.D.
President, American Medical Association

“Given the latest data showing the Omicron variant of SARS-CoV-2 is responsible for 99% of current COVID-19 infections, we are pleased that the FDA is following the scientific evidence and limiting the use of monoclonal antibody treatments to those that are effective against the Omicron variant. Limiting the use of these treatments will help ensure patients receive the best available therapy. We encourage physicians to reference the current National Institutes of Health (NIH) COVID-19 treatment guidelines for the latest information on authorized therapies and recommendations for their use.

“We continue to strongly urge every eligible individual to make sure they are up to date on their COVID-19 vaccinations, including booster doses. The Omicron variant is highly contagious and the unvaccinated remain most at risk of severe illness, hospitalization and death if infected. Data further suggests that a booster dose provides greater protection against the Omicron variant.”

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
What drives vaccine hesitancy?
Next article
Long-acting Antibody Treatment vs. Omicron Variant in Patients with Compromised Immune System

More Articles

Social Security Administration Corrects Millions of Records in Major Database Cleanup

The Social Security Administration (SSA) announced on October 20, 2026, that it has corrected millions of Social Security number records in what the agency describes as its most comprehensive record-integrity initiative in 91 years.

FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women

The U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week. The approval aligns with FDA’s Public Health Pillar: Increasing Access to Affordable Medicines & Medical Products.

A UTHealth Houston Physician Turned a Texas Teen’s Frightening Diagnosis into a Champion Title

Two years ago, Geordon Boulware, now 15, was at a routine dental visit in his hometown of Lufkin, Texas, when his dentist discovered he had an abnormal growth on his jaw. After meeting with a local oral surgeon, Geordon and his mom decided to seek treatment in Houston. 

Dr. Lisa Chapa Explains Why Not Every Breast Lump Is Cancer

 Discovering a lump in the breast can cause immediate concern, but many breast abnormalities are not cancerous, according to Dr. Lisa Chapa, a breast surgeon who explained how physicians distinguish benign conditions from breast cancer.
- Advertisement -